Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective

Journal of Clinical Virology

Volumn 58, Issue 1, 2013, Pages 67-73

  Wesdorp, D J W ^a   Knoester, M ^a   Braat, A E ^a   Coenraad, M J ^a   Vossen, A C T M ^a   Claas, E C J ^a   Van Hoek, B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Emtricitabine; Hepatitis B; Immunoglobulin; Liver transplantation; Prevention; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECURRENT INFECTION; SEROCONVERSION; SERUM; SIDE EFFECT; SLEEP DISORDER; SWEATING; UNSPECIFIED SIDE EFFECT;

EID: 84881550533     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.06.035     Document Type: Article

References (38)

1. Steinmuller T., Seehofer D., Rayes N., Muller A.R., Settmacher U., Jonas S., Neuhaus R., Berg T., Hopf U., Neuhaus P. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002, 35:1528-1535.
2. Kim W.R., Poterucha J.J., Kremers W.K., Ishitani M.B., Dickson E.R. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004, 10:968-974.
3. Harrison R.F., Davies M.H., Goldin R.D., Hubscher S.G. Recurrent hepatitis B in liver allografts: a distinctive form of rapidly developing cirrhosis. Histopathology 1993, 23:21-28.
4. Freeman R.B., Sanchez H., Lewis W.D., Sherburne B., Dzik W.H., Khettry U., Hing S., Zeldis J.B., Jenkins R.L. Serologic and DNA follow-up data from HBsAg-positive patients treated with orthotopic liver transplantation. Transplantation 1991, 51:793-797.
5. O'Grady J.G., Smith H.M., Davies S.E., Daniels H.M., Donaldson P.T., Tan K.C., Portmann B., Alexander G.J., Williams R. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992, 14:104-111.
6. Samuel D., Bismuth A., Mathieu D., Arulnaden J.L., Reynes M., Benhamou J.P., Brechot C., Bismuth H. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991, 337:813-815.
7. Samuel D., Muller R., Alexander G., Fassati L., Ducot B., Benhamou J.P., Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993, 329:1842-1847.
8. Grellier L., Mutimer D., Ahmed M., Brown D., Burroughs A.K., Rolles K., McMaster P., Beranek P., Kennedy F., Kibbler H., McPhillips P., Elias E., Dusheiko G. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996, 348:1212-1215.
9. Angus P.W., McCaughan G.W., Gane E.J., Crawford D.H., Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000, 6:429-433.
10. Roche B., Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004, 10:S74-S85.
11. EASL clinical practice guidelines Management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
12. Perrella A., Lanza A.G., Santaniello W., Pisaniello D., Dicostanzo G., Calise F., Amato G., Marcos A., Cuomo O. Telbivudin as prophylaxis for hepatitis B virus recurrence after liver transplantation: a case series in single-center experience. Transplant Proc 2012, 44:1986-1988.
13. Burbach G.J., Bienzle U., Neuhaus R., Hopf U., Metzger W.G., Pratschke J., Neuhaus P. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplantation 1997, 63:478-480.
14. Yahyazadeh A., Beckebaum S., Cicinnati V., Klein C., Paul A., Pascher A., Neuhaus R. Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Int 2011, 24:441-450.
15. Angus P.W., Patterson S.J., Strasser S.I., McCaughan G.W., Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008, 48:1460-1466.
16. Nath D.S., Kalis A., Nelson S., Payne W.D., Lake J.R., Humar A., Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant 2006, 20:206-210.
17. Saab S., Desai S., Tsaoi D., Durazo F., Han S., McClune A., Holt C., Farmer D., Goldstein L., Busuttil R.W. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011, 11:511-517.
18. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Ma J., Brosgart C.L., Borroto-Esoda K., Arterburn S., Chuck S.L. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743-1751.
19. Sung J.J., Lai J.Y., Zeuzem S., Chow W.C., Heathcote E.J., Perrillo R.P., Brosgart C.L., Woessner M.A., Scott S.A., Gray D.F., Gardner S.D. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008, 48:728-735.
20. Tenney D.J., Rose R.E., Baldick C.J., Pokornowski K.A., Eggers B.J., Fang J., Wichroski M.J., Xu D., Yang J., Wilber R.B., Colonno R.J. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503-1514.
21. Hou J., Yin Y.K., Xu D., Tan D., Niu J., Zhou X., Wang Y., Zhu L., He Y., Ren H., Wan M., Chen C., Wu S., Chen Y., Xu J., Wang Q., Wei L., Chao G., Constance B.F., Harb G., Brown N.A., Jia J. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008, 47:447-454.
22. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., Han S., Poynard T., Myers M., Chao G., Lloyd D., Brown N.A. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005, 129:528-536.
23. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., Chen Y., Heathcote E.J., Rasenack J., Bzowej N., Naoumov N.V., Di Bisceglie A.M., Zeuzem S., Moon Y.M., Goodman Z., Chao G., Constance B.F., Brown N.A. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-2588.
24. Liaw Y.F., Gane E., Leung N., Zeuzem S., Wang Y., Lai C.L., Heathcote E.J., Manns M., Bzowej N., Niu J., Han S.H., Hwang S.G., Cakaloglu Y., Tong M.J., Papatheodoridis G., Chen Y., Brown N.A., Albanis E., Galil K., Naoumov N.V. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.
25. Fung J., Cheung C., Chan S.C., Yuen M.F., Chok K.S., Sharr W., Dai W.C., Chan A.C., Cheung T.T., Tsang S., Lam B., Lai C.L., Lo C.M. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011, 141:1212-1219.
26. Samuel D., Roche B. Combined prophylaxis might still be better than monoprophylaxis with entecavir following liver transplantation for hepatitis B. Gastroenterology 2012, 142:e34-e35.
27. Heathcote E.J., Marcellin P., Buti M., Gane E., de Man R.A., Krastev Z., Germanidis G., Lee S.S., Flisiak R., Kaita K., Manns M., Kotzev I., Tchernev K., Buggisch P., Weilert F., Kurdas O.O., Shiffman M.L., Trinh H., Gurel S., Snow-Lampart A., Borroto-Esoda K., Mondou E., Anderson J., Sorbel J., Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011, 140:132-143.
28. Stravitz R.T., Shiffman M.L., Kimmel M., Puri P., Luketic V.A., Sterling R.K., Sanyal A.J., Cotterell A.H., Posner M.P., Fisher R.A. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int 2012, 32:1138-1145.
29. Liaw Y.F., Sheen I.S., Lee C.M., Akarca U.S., Papatheodoridis G.V., Suet-Hing W.F., Chang T.T., Horban A., Wang C., Kwan P., Buti M., Prieto M., Berg T., Kitrinos K., Peschell K., Mondou E., Frederick D., Rousseau F., Schiff E.R. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53:62-72.
30. Teperman L., Spivey J.R., Poordad F., Schiano T., Bzowej N., Pungpapong S. Emtricitabine-tenofovir DF combination±HBIG post/orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results. J Hepatol 2010, 52:S12-S13.
31. Marcellin P., Chang T.T., Lim S.G., Sievert W., Tong M., Arterburn S., Borroto-Esoda K., Frederick D., Rousseau F. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750-758.
32. Yeon J.E., Yoo W., Hong S.P., Chang Y.J., Yu S.K., Kim J.H., Seo Y.S., Chung H.J., Moon M.S., Kim S.O., Byun K.S., Lee C.H. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006, 55:1488-1495.
33. Baldick C.J., Eggers B.J., Fang J., Levine S.M., Pokornowski K.A., Rose R.E., Yu C.F., Tenney D.J., Colonno R.J. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008, 48:895-902.
34. Ueda Y., Marusawa H., Kaido T., Ogura Y., Ogawa K., Yoshizawa A., Hata K., Fujimoto Y., Nishijima N., Chiba T., Uemoto S. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res 2013, 43:67-71.
35. Cai C.J., Lu M.Q., Chen Y.H., Zhao H., Li M.R., Chen G.H. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant 2012, 26:208-215.
36. Cholongitas E., Vasiliadis T., Antoniadis N., Goulis I., Papanikolaou V., Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012, 14:479-487.
37. Cholongitas E., Papatheodoridis G.V. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B Virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013, 13:353-362.
38. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608.